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Epidemiology of Methicillin-Resistant Staphylococcus aureus
Colonization in a Surgical Intensive Care Unit
David K. Warren, MD, MPH; Rebecca M. Guth, RRT, MPH; Craig M. Coopersmith, MD; Liana R. Merz, MPH;
Jeanne E. Zack, RN, BSN, CIC; Victoria J. Fraser, MD
background. Methicillin-resistant Staphylococcus aureus (MRSA) is a cause of healthcare-associated infections among surgical intensive
care unit (ICU) patients, though transmission dynamics are unclear.
objective. To determine the prevalence of MRSA nasal colonization at ICU admission, to identify associated independent risk factors,
to determine the value of these factors in active surveillance, and to determine the incidence of and risk factors associated with MRSA
acquisition.
design. Prospective cohort study.
setting. Surgical ICU at a teaching hospital.
patients. All patients admitted to the surgical ICU.
results. Active surveillance for MRSA by nasal culture was performed at ICU admission during a 15-month period. Patients who stayed
in the ICU for more than 48 hours had nasal cultures performed weekly and at discharge from the ICU, and clinical data were collected
prospectively. Of 1,469 patients, 122 (8%) were colonized with MRSA at admission; 75 (61%) were identified by surveillance alone. Among
775 patients who stayed in the ICU for more than 48 hours, risk factors for MRSA colonization at admission included the following:
hospital admission in the past year (1-2 admissions: adjusted odds ratio [aOR], 2.60 [95% confidence interval {CI}, 1.47-4.60]; more than
2 admissions: aOR, 3.56 [95% CI, 1.72-7.40]), a hospital stay of 5 days or more prior to ICU admission (aOR, 2.54 [95% CI, 1.49-4.32]),
chronic obstructive pulmonary disease (aOR, 2.16 [95% CI, 1.17-3.96]), diabetes mellitus (aOR, 1.87 [95% CI, 1.10-3.19]), and isolation
of MRSA in the past 6 months (aOR, 8.18 [95% CI, 3.38-19.79]). Sixty-nine (10%) of 670 initially MRSA-negative patients acquired MRSA
in the ICU (corresponding to 10.7 cases per 1,000 ICU-days at risk). Risk factors for MRSA acquisition included tracheostomy in the ICU
(aOR, 2.18 [95% CI, 1.13-4.20]); decubitus ulcer (aOR, 1.72 [95% CI, 0.97-3.06]), and receipt of enteral nutrition via nasoenteric tube
(aOR, 3.73 [95% CI, 1.86-7.51]), percutaneous tube (aOR, 2.35 [95% CI, 0.74-7.49]), or both (aOR, 3.33 [95% CI, 1.13-9.77]).
conclusions. Active surveillance detected a sizable proportion of MRSA-colonized patients not identified by clinical culture. MRSA
colonization on admission was associated with recent healthcare contact and underlying disease. Acquisition was associated with potentially
modifiable processes of care.
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Staphylococcus aureus is one of the most frequent causes of
nosocomial infection in intensive care unit (ICU) patients.1
The proportion of S. aureus isolates with methicillin resistance
is increasing in both the United States and several European
countries.2,3 Nasal colonization with S. aureus predisposes to
subsequent infection, particularly in surgical patients.4-6 In-
fections caused by methicillin-resistant S. aureus (MRSA)
have been associated with increased mortality and hospital
costs, compared with methicillin-susceptible strains.7-9
Unidentified MRSA carriers serve as a potential reservoir
for transmission.10 Active surveillance for MRSA, using screen-
ing cultures and aggressive contact precautions, has been shown
to reduce MRSA transmission.10-12 The use of active surveillance
helps in the determination of the prevalence and incidence of
MRSA colonization in a given area or institution, though some
studies have had incomplete data for admission screening
cultures,13,14 potentially leading to biased estimates of these val-
ues. In addition, screening of all patients may be an over-
whelming and costly task. Screening of patients at high-risk
and those with known risk factors for MRSA colonization may
be more feasible. Selective screening of patients for MRSA,
combined with aggressive infection control measures, has been
demonstrated to be an effective and cost-effective method to
reduce MRSA transmission.11,12,15,16 However, selective screen-
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ing methods are often chosen on the basis of generalized risk
factors rather than identified patient-specific risk factors in a
given patient population.
The purpose of this study was to implement active sur-
veillance for MRSA in a surgical ICU and to obtain high
capture rates for admission surveillance cultures in order to
accurately determine the prevalence of MRSA nasal coloni-
zation at ICU admission. Independent risk factors associated
with MRSA colonization on admission were also ascertained,
and the predictive value of the multivariate model was de-
termined to assess the value of these factors as a screening
tool for future active surveillance. In addition, we sought to
determine the incidence of and risk factors associated with
MRSA acquisition.
methods
This was a 15-month prospective cohort study conducted
from December 2002 through February 2004 in the surgical
ICU at Barnes-Jewish Hospital (BJH). BJH is a 1,251-bed,
urban, tertiary care teaching hospital in St. Louis, Missouri.
The burn, trauma, and surgical ICU has 24 beds and ap-
proximately 1,400 admissions per year.
MRSA active surveillance was instituted in the surgical ICU
by the hospital infection control department in December
2002. Nasal culture for S. aureus was performed for all pa-
tients admitted to the ICU who stayed for more than 12 hours.
Nasal swab specimens for culture were also obtained weekly
and at discharge from the ICU for all patients who stayed in
the ICU for more than 48 hours. A specimen was collected
from both anterior nares of each patient. Collected specimens
were transported and stored at room temperature. Mannitol
salt agar plates (Becton Dickinson) were inoculated directly
with swab specimens. The mannitol salt agar plates were in-
cubated for 24-48 hours at 35C and examined for growth.
Strains that produced yellow colonies on the screening man-
nitol salt agar plates were confirmed as S. aureus by means
of Gram staining, 3% catalase testing, and coagulase testing
with the Staph Latex agglutination assay (LifeSign). Detection
of MRSA was performed by subculturing confirmed S. aureus
isolates in Trypase soy broth with 5% sheep blood (Becton
Dickinson), then on oxacillin screening agar containing 6.0
mg/mL of oxacillin (Becton Dickinson). Plates were incubated
at 35C for 18-24 hours and examined for evidence of growth.
Strains showing distinct growth were considered to be meth-
icillin resistant.
Data collected for all study patients included demographic
characteristics, hospital and ICU admission dates, admission
to BJH in the past 12 months, location prior to hospital
admission (ie, home, another hospital, or a long-term care
facility), use of contact precautions, and hospital and ICU
discharge dates and discharge status. Additional data were
collected for patients who remained in the ICU for more than
48 hours, including past medical history, ICU processes of
care and medications received, and use of mechanical ven-
tilation and/or central venous catheters. Each nasoenteric
tube used was identified as a nasogastric or Dobhoff tube.
Each percutaneous feeding tube was defined as a gastrostomy,
jejunostomy, or gastrojejunostomy tube. In accordance with
hospital policy, patients found to be colonized or infected
with MRSA, vancomycin-resistant enterococci (VRE), Clos-
tridium difficile (associated with diarrhea), and certain mul-
tidrug-resistant, gram-negative bacilli were placed under con-
tact precautions. In addition, patients with a history of
colonization with these organisms were identified and placed
under contact precautions at admission. Decolonization ther-
apy for MRSA was not routinely done. All positive clinical
culture results and ICU-related infections were recorded. In-
fections were defined using the National Nosocomial Infec-
tion Surveillance system criteria.17
MRSA colonization at admission was defined as an ad-
mission nasal surveillance culture positive for MRSA or any
clinical culture positive for MRSA within 48 hours after ICU
admission. MRSA acquisition was defined as an admission
nasal surveillance culture negative for MRSA and subsequent
isolation of MRSA from a surveillance or clinical culture per-
formed more than 48 hours after admission. Incidence den-
sity was calculated as the number of cases of MRSA acqui-
sition per 1,000 total patient-days and per 1,000 days at risk
for MRSA colonization (ie, days on which a given patient
had no MRSA detected). At-risk ICU-days were calculated
by excluding from the denominator the ICU-days of patients
colonized with MRSA on admission, and only including pa-
tient-days occurring prior to MRSA colonization for those
acquiring MRSA in the ICU.
Statistical analysis was performed using SPSS for Windows,
version 12.0 (SPSS). Sensitivity, specificity, and positive and
negative predictive values were all calculated using standard
methodology.18 Categorical variables were analyzed using the
x2 test or Fisher’s exact test, as appropriate, and analysis of
continuous variables was performed using the Wilcoxon
rank-sum test. Two-tailed tests were used, and wasP ! .05
considered statistically significant. Previously known risk fac-
tors or clinically relevant significant variables from the uni-
variate analysis were considered for inclusion in multivariate
logistic regression analysis. Backward stepwise logistic re-
gression was performed, and the model that was considered
biologically plausible and had the lowest 2 log likelihood
ratio was chosen as the final model. Variables were tested for
first-order interaction effects, and none were noted. The Hos-
mer and Lemeshow goodness-of-fit test was used to assess
model fit. The Washington University Institutional Review
Board approved this study.
results
During the study period, 1,469 (98%) of 1,494 patients ad-
mitted to the ICU had an admission nasal culture performed.
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table 1. Demographic Characteristics of 775 Patients Who
Stayed in the Surgical Intensive Care Unit (ICU) for More Than 48
Hours for Whom a Nasal Swab Specimen Was Obtained at
Admission
Variable Value
Baseline patient characteristics
Male sex 458 (59)
Age in years
Median (range) 60 (17-97)
Mean 58
White race 585 (76)
Contact precautions at time of ICU admission 82 (11)
Admission to BJH in past 12 months
None 539 (70)
1-2 admissions 170 (22)
12 admissions 66 (8)
Location prior to hospital admission
Home 608 (78)
Long-term care facility 21 (3)
Other hospital 146 (19)
Pre-ICU LOS in days
Median (range) 0 (0-143)
Mean 4
Conditions present at admission
Congestive heart failure 79 (10)
COPD 106 (14)
Malignancy (current diagnosis) 129 (17)
Chemotherapy (in the past 28 days) 11 (1)
Chronic skin disease 8 (1)
Diabetes mellitus 187 (24)
Systemic corticosteroid use (in the past 28 days) 58 (8)
Baseline renal function
Normal 690 (89)
Chronic renal failure 58 (8)
Chronic renal failure with dialysis 27 (4)
Cirrhosis 36 (5)
Solid organ or bone marrow transplant 15 (2)
Surgical procedure
Prior to admission (within past 3 months) 150 (19)
Current hospitalization 633 (82)
Burn patient 11 (1)
Antibiotic use and resistant organisms
MRSA isolated in past 6 months 29 (4)
Any infection in past 3 months 143 (18)
Antibiotic use in past 3 months 160 (21)
C. difficile–associated diarrhea in past 3 months 19 (2)
VRE isolated in past 3 months 38 (5)
MRSA colonized on admission 82 (11)
ICU-related events
Tracheostomy
None 585 (76)
Present on admission to ICU 27 (3)
Performed while in ICU 163 (21)
Decubitus ulcer in ICU 171 (22)
CVC
Present 539 (71)
Duration, median total CVC–days (range) 7 (0-63)
(Continued)
table 1. (Continued)
Variable Value
Mechanical ventilation
Received 592 (76)
Median ventilator-days (range) 4 (0-66)
Reintubation 85 (11)
Systemic corticosteroid use 73 (9)
Antacid use 41 (5)
H2 antagonist use 667 (86)
Sucralfate use 7 (1)
Vasopressor use 299 (39)
Enteral nutrition
None 483 (62)
Via nasoenteric tubea 212 (27)
Via percutaneous tubeb 43 (6)
Via nasoenteric and percutaneous tube 37 (5)
Total parenteral nutrition 224 (29)
Outcomes
Median ICU LOS in days (range) 6 (3-76)
Median hospital LOS in days (range) 19 (4-219)
Hospital discharge status
Death 109 (14)
Discharged home 349 (45)
Discharged to LTC facility 277 (36)
Discharged to other hospital 40 (5)
note. Data are no. (%) of patients, unless otherwise specified. BJH,
Barnes-Jewish Hospital; COPD, chronic obstructive pulmonary disease; CVC,
central venous catheter; LOS, length of stay, LTC, long-term care; MRSA,
methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant
enterococci.
a Nasoenteric tube includes nasogastric tubes and Dobhoff tubes.
b Percutaneous tube includes gastrostomy, jejunostomy, and gastrojejunos-
tomy tubes.
Of those from whom a nasal swab specimen was obtained,
122 (8%) were colonized with MRSA on admission to the
ICU. Of these 122 patients, 75 (61%) had MRSA colonization
detected by surveillance culture alone while they were in the
ICU. Two patients (2%) had MRSA colonization detected by
clinical culture alone.
Risk factor analysis was performed only for the 775 (53%)
patients who stayed in the ICU for more than 48 hours and
had a nasal swab specimen obtained at admission (Table 1).
The median age of admitted patients was 60 years (range,
17-97 years), and 458 (59%) were male. Eighty-two (11%)
of 775 patients who stayed in the ICU more than 48 hours
were colonized with MRSA (Table 2). Patients with MRSA
colonization on admission were likely to have had recent
healthcare contact, defined as admission to BJH in the past
year, admission from a long-term care facility or from another
hospital, or a pre-ICU hospital length of stay of at least 5
days, compared with patients who were not colonized on
admission (85% vs 52%, ). On multivariate testing,P ! .001
factors independently associated with MRSA colonization on
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table 2. Comparison of Patients With and Patients Without Methicillin-Resistant Staphylococcus aureus
(MRSA) Colonization on Admission to the Surgical Intensive Care Unit (ICU)
Variable
Univariate analysis, value
Multivariate
analysis: aORa
(95% CI)
Patients
with MRSA
(n p 693)
Patients
without MRSA
(n p 82) P
Male 408 (59) 50 (61) .714
Median age in years (range) 59 (17-97) 67 (23-96) .008
Race (white) 520 (75) 65 (79) .400
Admission to BJH in past 12 months
None 507 (73) 32 (39) Refb,c Ref
1-2 admissions 140 (20) 30 (37) !.001 2.60 (1.47-4.60)
12 admissions 46 (7) 20 (24) !.001 3.56 (1.72-7.40)
Location prior to hospital admission
Home 552 (80) 56 (68) Refb
Long-term care facility 13 (2) 8 (10) !.001
Other hospital 128 (18) 18 (22) .257
Pre-ICU LOS of x5 days 132 (19) 36 (44) !.001 2.54 (1.49-4.32)
Conditions present at admission
Congestive heart failure 63 (9) 16 (20) .003
COPD 84 (12) 22 (27) !.001 2.16 (1.17-3.96)
Malignancy (current diagnosis) 114 (16) 15 (18) .672
Chemotherapy (in the past 28 days) 8 (1) 3 (4) .101
Chronic skin disease 7 (1) 1 (1) .593
Diabetes mellitus 152 (22) 35 (43) !.001 1.87 (1.10-3.19)
Systemic corticosteroid use (in the past 28 days) 49 (7) 9 (11) .204
Baseline renal function
Normal 623 (90) 67 (82) Refb
CRF 45 (6) 13 (16) .004
CRF with dialysis 25 (4) 2 (2) .692
Cirrhosis 32 (5) 4 (5) .786
Solid organ or bone marrow transplant 14 (2) 1 (1) 1.0
Surgical procedure
Prior to admission (in the past 90 days) 120 (17) 30 (37) !.001
During current ICU stay 562 (81) 71 (87) .224
Burn patient 11 (2) 0 (0) .617
Tracheostomy present at admission 20 (3) 7 (8) .018
Antibiotic use and resistant organisms
MRSA isolated in past 6 months 11 (2) 18 (22) !.001 8.18 (3.38-19.79)
Any infection in past 3 months 108 (16) 35 (43) !.001
Antibiotic use in past 3 months 125 (18) 35 (43) !.001
C. difficile–associated diarrhea in past 3 months 11 (2) 8 (10) !.001
VRE isolated in past 3 months 26 (4) 12 (15) !.001
note. Data are no. (%) of patients, unless otherwise specified. aOR, adjusted odds ratio; BJH, Barnes-Jewish Hospital; C.
difficile, Clostridium difficile; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; LOS, length of stay;
Ref, reference category; VRE, vancomycin-resistant enterococci.
a Other variables considered for inclusion into the final model: admission from a long-term care facility, infection in the past
3 months, antibiotic use in past 3 months, C. difficile–associated diarrhea in past 3 months, VRE colonization in past 3 months,
and surgical procedure in the 3 months prior to admission.
b Obtained from univariate logistic regression analysis.
c x2 for trend, 48.31; .P ! .001
admission were as follows: 1 or 2 admissions to BJH in the
past year (adjusted odds ratio [aOR], 2.60 [95% confidence
interval {CI}, 1.47-4.60]), more than 2 admissions to BJH in
the past year (aOR, 3.56; 95% CI, 1.72-7.40]), a hospital
length of stay of 5 days or more prior to admission to the
surgical ICU (aOR, 2.54 [95% CI, 1.49-4.32]), chronic ob-
structive pulmonary disease (aOR, 2.16 [95% CI, 1.17-3.96),
diabetes mellitus (aOR, 1.87 [95% CI, 1.10-3.19), and iso-
lation of MRSA in the past 6 months (aOR, 8.18 [95% CI,
3.38-19.79]) (Table 2).
The predictive ability of the model to detect MRSA col-
onization on admission in patients who stayed in the ICU
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table 3. Sensitivity and Specificity of Independent Risk Factor Variables for Prediction of
Methicillin-Resistant Staphylococcus aureus (MRSA) Colonization Among Patients Who Stayed
in the Surgical Intensive Care Unit (ICU) for More Than 48 Hours
Variable
Sensitivity,
%
Specificity,
%
Percentage of
patients admitted
to ICU
One predictor variable
A: Admission to BJH in past year 61 73 30
B: Pre-ICU LOS of x5 days 44 81 22
C: MRSA isolated in the past 6 months 22 98 4
D: Chronic obstructive pulmonary disease 27 88 14
E: Diabetes mellitus 43 78 24
Predictor variable A, B, or C 79 61 43
Any predictor variable 89 45 58
note. BJH, Barnes-Jewish Hospital; LOS, length of stay.
figure Distribution of the study population. Data are no. (%)
of patients. ICU, intensive care unit, MRSA, methicillin-resistant
Staphylococcus aureus. aOne patient did not have a follow-up nasal
swab specimen obtained but was determined to be MRSA positive
by clinical culture and was included in the analysis.
for more than 48 hours is shown in Table 3. Presence of at
least 1 of the independent risk factors had a sensitivity of
89% and a specificity of 45% for identification of a patient
with MRSA colonization on admission. Use of the risk factors
as a screening tool for active surveillance would lower the
percentage of ICU patients from whom admission surveil-
lance swab specimens were required to 58%. In this cohort,
the positive predictive value of this screening method was
16%, and the negative predictive value was 97%.
Of the 693 patients who were initially culture negative for
MRSA and who remained in the ICU for more than 48 hours,
669 (97%) had at least 1 follow-up nasal surveillance culture
performed (range, 1-10 cultures). One additional patient did
not have a follow-up nasal culture performed but was found
to be MRSA positive by routine clinical culture and was in-
cluded in the analysis (Figure). Sixty-nine patients (10%)
were newly colonized with MRSA on follow-up (9.5 cases per
1,000 ICU-days; 10.7 cases per 1,000 patient-days at risk).
The median time to culture positivity was 8 days (range, 2-24
days). Twenty-seven (39%) of 69 patients were identified by
surveillance culture alone, and another 5 (7%) were detected
by routine clinical culture alone. The time from the culture
date (ie, the date the swab specimen for culture was obtained)
to the availability of results was a median of 3 days. Of the
patients who acquired MRSA, 16 (23%) developed an MRSA
infection during their ICU stay (8 bloodstream infections, 3
cases of ventilator-associated pneumonia, and 5 other infec-
tions [eg, intra-abdominal abscess, surgical site infection, or
pneumonia]).
Risk factors associated with acquisition of MRSA in the sur-
gical ICU on univariate analysis are shown in Table 4. Risk
factors included in the final multivariate model were trache-
ostomy in the ICU (aOR, 2.18 [95% CI, 1.13-4.20]), devel-
opment of a decubitus ulcer while in the ICU (aOR, 1.72 [95%
CI, 0.97-3.06]), and enteral nutrition via nasoenteric tube
(aOR, 3.51 [95% CI, 1.74 to 7.07]), via percutaneous feeding
tube (aOR, 2.35 [95% CI, 0.74-7.49]), or both nasoenteric and
percutaneous tube (aOR, 3.33 [95% CI, 1.13-9.77]) (Table 4).
The presence of decubitus ulcers was retained in the multi-
variate model, even though the P value was greater than .05,
because the aORs of the other variables changed more than
10% when the risk factor was removed from the model.
discussion
Multiple studies have performed active surveillance for MRSA
and examined risk factors associated with MRSA coloniza-
tion, though few have achieved the extremely high initial
surveillance culture capture rates achieved in this study pop-
ulation. Nasal specimens for surveillance culture were ob-
tained from 98% of all patients admitted to the ICU in this
study, increasing the validity of the MRSA prevalence esti-
mate. Eight percent of all patients admitted to this ICU were
already colonized with MRSA. Other ICU populations have
reported admission prevalence rates of 4%-9%.12-14,19 Of the
patients colonized with MRSA on admission, 61% never had
an MRSA-positive clinical culture during their ICU stay.
table 4. Analysis of Risk Factors and Outcomes Associated With Acquisition of Methicillin-Resistant
Staphylococcus aureus (MRSA) During Surgical Intensive Care Unit Stay
Variable
Univariate analysis, value
Multivariate
analysis: aORa
(95% CI)
Patients
with MRSA
(n p 601)
Patients
without MRSA
(n p 69) P
Patient characteristics
Male sex 353 (59) 41 (59) .913
Age, median years (range) 60 (17-94) 57 (19-96) .998
White race 453 (75) 48 (70) .293
Conditions present at admission
Congestive heart failure 52 (9) 11 (16) .049
COPD 68 (11) 14 (20) .031
Malignancy (current diagnosis) 105 (18) 7 (10) .122
Chemotherapy (in the past 28 days) 8 (1) 0 (0) 1.0
Chronic skin disease 6 (1) 1 (1) .534
Diabetes mellitus 126 (21) 21 (30) .072
Systemic corticosteroid use (in the past 28 days) 42 (7) 5 (7) 1.0
Renal function
Normal 540 (90) 62 (90) Refb
CRF 37 (6) 7 (10) .249
CRF with dialysis 24 (4) 0 (0) .998
Cirrhosis 32 (5) 0 (0) .065
Solid organ or bone marrow transplant 14 (2) 0 (0) .382
Surgical procedure
Prior to admission (in the past 90 days) 110 (18) 7 (10) .091
Current admission 486 (81) 63 (91) .033
Burn patient 9 (2) 1 (1) 1.0
Antibiotic use and resistant organisms
MRSA isolated in past 6 months 6 (1) 4 (6) .013
Any infection in past 3 months 91 (15) 12 (17) .599
Antibiotic use in past 3 months 112 (19) 9 (13) .253
C. difficile–associated diarrhea in past 3 months 11 (2) 0 (0) .615
VRE isolated in past 3 months 20 (3) 4 (6) .297
ICU-related events
Tracheostomy performed while in ICU 106 (18) 37 (54) !.001 2.18 (1.13-4.20)
Decubitus ulcer 115 (19) 32 (46) !.001 1.72 (0.97-3.06)c
CVC
Present 404 (67) 58 (84) .004
Duration, median CVC-days (range) 7 (0-63) 14 (0-62) !.001
Mechanical ventilation
Received 443 (74) 62 (90) .003
Duration, median ventilator-days (range) 3 (0-66) 15 (0-60) !.001
Reintubation 60 (10) 13 (19) .025
Systemic corticosteroid use 53 (9) 7 (10) .715
Antacid use 31 (5) 4 (6) .775
H2 antagonist use 515 (86) 62 (90) .343
Sucralfate use 6 (1) 0 (0) 1.0
Vasopressor use 206 (34) 40 (58) !.001
Enteral nutrition
None 400 (67) 17 (25) Refb Ref
Via nasoenteric feeding tube 148 (25) 38 (55) !.001 3.51 (1.74-7.07)
Via percutaneous feeding tube 28 (5) 5 (7) .008 2.35 (0.74-7.49)
Via nasoenteric and percutaneous tube 25 (4) 9 (13) .001 3.33 (1.13-9.77)
Total parenteral nutrition 163 (27) 20 (29) .742
Outcomes
Median ICU LOS in days (range) 6 (3-66) 18 (3-76) !.001
Median hospital LOS in days (range) 18 (4-219) 28 (7-96) !.001
Death during hospitalization 65 (11) 14 (20) .021
note. Data are no. (%) of patients, unless otherwise specified. aOR, adjusted odds ratio; C. difficile, Clostridium
difficile; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; CVC, central venous catheter;
LOS, length of stay; Ref, reference category; VRE, vancomycin-resistant enterococci.
a Other variables considered for inclusion into the model: no. of CVC-days, no. of mechanical ventilation–days,
and vasopressor use.
b Obtained from univariate logistic regression.
c Retained in final model because of its confounding effect (see Methods).
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Other studies have found similar detection rates, with only
25%-60% of all MRSA-colonized patients detected by routine
clinical culture.12,19-22 There is ongoing debate concerning the
effectiveness of contact precautions to reduce transmission
of MRSA or other antibiotic-resistant organisms.22 However,
reliance on routine clinical cultures alone leaves many MRSA
carriers undetected, which is likely to compromise the overall
success of infection control measures.
Patients with a history of MRSA colonization in the pre-
vious 6 months were 8 times more likely to be colonized with
MRSA on admission to the ICU. Estimates of long-term per-
sistence of MRSA colonization vary widely, from several
months to more than 3 years.23-26 Decolonization therapy,
including intranasal mupirocin therapy and chlorhexidine
baths, have been used with varying degrees of success to
decrease the prevalence of long-term colonization.27 The ef-
ficacy of these methods depends on the antimicrobial agent,
the body site, and whether MRSA is endemic in a particular
setting.27 Future studies are planned in our ICU in which
decolonization therapy will be implemented to reduce the
prevalence of MRSA colonization.
Recent healthcare contact was a predominant risk factor
associated with MRSA colonization on admission in the sur-
gical ICU in this study, which is a common finding in other
investigations.12,19,20 Both previous admission to BJH and a
hospital length of stay of 5 days or more prior to admission
to the surgical ICU were associated with increased risk, which
suggests ongoing institutional transmission of MRSA. Eighty-
five percent of the patients colonized with MRSA on admis-
sion had had some form of recent healthcare contact (recent
hospital admission, admission from a long-term care facility
or from another hospital, or a hospital length of stay of 5
days or more prior to admission to the surgical ICU). How-
ever, 15% of patients colonized with MRSA at admission did
not have some identifiable healthcare contact in the past year,
which raises the possibility of community-acquired MRSA
colonization. Without molecular typing of isolates for deter-
minants associated with community-acquired MRSA, such as
SCCmec type IV,28 this cannot be proven at this time.
Patients with chronic diseases, such as COPD or diabetes
mellitus, had a higher likelihood of MRSA colonization on
admission. Diabetes has been identified as a risk factor for
MRSA colonization at hospital admission,29 but COPD is gen-
erally not recognized as a common risk factor. Although it is
controversial, antibiotic therapy is frequently prescribed for
COPD exacerbations and may lead to increased antibiotic re-
sistance in these patients.30 There was no difference in antibiotic
use in the 3 months prior to admission between patients with
and patients without COPD, which would argue against this
explanation. However, there were limited data available to es-
tablish a patient’s history of antibiotic use prior to hospital
admission, and it is unlikely that information on all previous
antibiotic use was captured, particularly antibiotic therapy re-
ceived at other hospitals or through outpatient treatment.
Active screening of all patients on admission is labor- and
resource intensive. Girou et al.12 found that selective screening
for MRSA based on risk factors was as effective as screening
all patients in detecting colonized patients, but this selective
strategy was not determined to be a cost-effective strategy in
a larger study.19 In our study, screening by significant pre-
dictor variables from multivariate analysis would identify 89%
of MRSA colonized patients at admission and would decrease
the total number of admission surveillance cultures required
by 42%, assuming that the group of all patients admitted to
the ICU had the same frequency of risk factors as did the
group who stayed in the ICU for more than 48 hours.
Whether this approach would identify sufficient numbers of
patients colonized with MRSA on admission to reduce trans-
mission in this setting remains to be determined. Increased
community-acquired MRSA may also alter the efficacy of
such risk-based screening.
In this study, 10% of patients in the surgical ICU acquired
MRSA. Estimates in the literature of rates of acquisition in an
ICU vary from 4% to 11%.12-14 The MRSA acquisition rate in
our ICU was 10.7 cases per 1,000 ICU-days at-risk. This value
reflects a more accurate estimate of incidence, as it accounts
for length of stay in the ICU before the time of MRSA colo-
nization, as opposed to including all ICU-days in the denom-
inator. Others have used the total number of patient-days to
calculate the incidence density of MRSA colonization,31,32 which
would underestimate the true acquisition rate.
This study mainly focused on patient risk factors and pro-
cesses of care associated with MRSA acquisition. All of the
predictors in the multivariate model are indicators of in-
creased severity of illness, which potentially raises the inten-
sity of care and time of contact with healthcare professionals.
MRSA colonization in wounds and skin ulcers is well doc-
umented.21,25,33 Microbial contamination of tube feeding so-
lution has been associated with nosocomial infection.34 In
this study, tube feeding via a percutaneous tube alone did
not significantly elevate the risk of MRSA acquisition in the
multivariate model, suggesting that the route was the risk
factor, rather than tube feeding solution itself. Dziekan et al.35
identified the presence of a nasogastric tube as a risk factor
for MRSA colonization, further supporting this theory. More
research is needed to determine the impact of nasoenteric
tubes on MRSA nasal colonization.
There are some limitations to this study. Because of logis-
tical constraints, comorbidity and process of care data were
collected only for patients who remained in the ICU for more
than 48 hours; brief ICU stays may contribute to the trans-
mission of MRSA but were not captured by this analysis. In
addition, a severity-of-illness measure (eg, Acute Physiology
and Chronic Health Evaluation II score) was not available
for all patients for inclusion in risk factor analysis. However,
surrogate markers, such as information on vasopressor use
and use of mechanical ventilation, were available. Other in-
formation that could not be reliably ascertained for all sub-
jects was admission to other healthcare facilities in the past
epidemiology of mrsa colonization in an icu 1039
year, which may have been a risk factor for MRSA coloni-
zation on admission.
Specimens for surveillance culture were only taken from
the nares. The use of nasal cultures alone for the detection
of MRSA colonization has a sensitivity of 78%-85%,12,19,21
compared with use of surveillance cultures of specimens from
multiple body sites. Therefore, several patients who were clas-
sified as having acquired MRSA may have already been col-
onized at admission. Four of 10 patients with a history of
prior MRSA colonization were culture negative for MRSA on
admission and were culture positive on subsequent follow-
up testing, suggesting they were colonized with MRSA on
admission. Performance of additional cultures of specimens
from other body sites may increase the detection of MRSA
carriage but would result in increased cost of surveillance. In
addition, surveillance cultures were only performed weekly
and at discharge, which may underestimate the overall in-
cidence density. Finally, molecular typing of MRSA isolates
would enhance our understanding of MRSA transmission in
this population but was not feasible with current resources.
A significant number of patients admitted to the ICU in
this study were colonized with MRSA. Sixty-one percent of
MRSA-colonized patients identified by nasal culture on ad-
mission would not have been identified by routine clinical
culture in the ICU. Risk factors for MRSA colonization on
admission include recent colonization with MRSA, recent
healthcare contact, and presence of an underlying illness, such
as COPD, which is not a commonly identified risk factor.
Another 10% of patients acquired MRSA despite infection
control measures. Acquisition was associated with acuity of
care and processes of care, including enteral feeding via na-
soenteric tube. This important baseline data will facilitate
future interventions necessary to limit MRSA transmission
in this ICU.
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